The fight against the coronavirus (SARS-CoV-2) continues into 2021. While effective prophylaxis is now possible with vaccines, breakthrough innovations in treatment of Covid-19 patients are still awaited.<\/p>\n
Among the promising approaches being pursued is one by Aphaia Pharma in cooperation with the University of Toronto. The research focuses on a hormone that regulates blood glucose levels in humans: glucagon-like peptide 1 (GLP-1). One of its many functions is that GLP-1 activates processes that strengthen the barrier function of cells, possibly impeding the penetration of SARS-CoV-2. The development of GLP-1-based agents could be a viable therapeutic approach to slow the progression of COVID-19 and improve clinical outcomes following SARS-CoV-2 infection, in people with and without pre-existing conditions.<\/p>\n
Interestingly, Aphaia Pharma\u2019s therapeutic target group, i.e. people with pre-existing conditions such as diabetes and obesity, who have a reduced GLP-1 release, are among the most critical Covid-19 risk groups. Aphaia Pharma specialises in treatments for the metabolic syndrome, and an endocrine-acting COVID-19 drug would be a valuable addition to its therapeutic offerings.<\/p>\n","protected":false},"excerpt":{"rendered":"
The fight against the coronavirus (SARS-CoV-2) continues into 2021. While effective prophylaxis is now possible with vaccines, breakthrough innovations in treatment of Covid-19 patients are still awaited. Among the promising approaches being pursued is one by Aphaia Pharma in cooperation with the University of Toronto. The research focuses on a hormone that regulates blood glucose […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-604","post","type-post","status-publish","format-standard","hentry","category-important"],"acf":[],"_links":{"self":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/comments?post=604"}],"version-history":[{"count":3,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/604\/revisions"}],"predecessor-version":[{"id":878,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/604\/revisions\/878"}],"wp:attachment":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/media?parent=604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/categories?post=604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/tags?post=604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}